Journal of International Psychiatry

Abstracts: Objective: To investigate the clinical effect on cognitive function between valproate adding ziprasidone or olanzapine in patients with bipolar disorder I type. Methods: A controlled randomized clinical trial was conducted from Feb , 2015 to Jan, 2016. A total of 120 patients with bipolar disorder I type were randomized into two groups: A group (valproate and ziprasidone) and B group (valproate and olanzapine). The condition of patients were assessed by bech rafaelsen mania rating scale (BRMS). Cognitive function were evaluated by montreal cognitive assessment (MoCA), including trail markingtest, digital symbol, digital span and wisconsin card sorting test. Personal and social function scale (PSP) were used to evaluate the efficacy and effect on social function. Results: After treatment the BRMS scores of the two groups were decreased significantly than before treatment, the difference between the two groups had no statistical significance (P＞0.05). Cognitive function in the two groups had improved apparently. The trail markingtest, digital symbol, digital span and wisconsin card sorting test scores in A group were significantly better than those in B group (P＜0.05). The PSP scores of the two groups were increased significantly than before treatment, and the difference between the two groups had statistical significance (P＜0.05). Conclusions: The cognitive function can be improved in patients with bipolar disorder I type treating with valproate adding ziprasidone or olanzapine; however, valproate adding ziprasidone is better.

valproate; ziprasidone; olanzapine; bipolar disorder I type